Dupuytren's Disease Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Endo Pharma, Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences

DelveInsight's "Dupuytren's Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Dupuytren's Disease, historical and forecasted epidemiology as well as the Dupuytren's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Dupuytren's Disease, offering comprehensive insights into the Dupuytren's Disease revenue trends, prevalence, and treatment landscape. The report delves into key Dupuytren's Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dupuytren's Disease therapies. Additionally, we cover the landscape of Dupuytren's Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dupuytren's Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dupuytren's Disease space.

To Know in detail about the Dupuytren's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dupuytren's Disease Market Forecast [https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Dupuytren's Disease Market Report:

*
The Dupuytren's Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In July 2024, Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients. Dupuytren's contracture is a debilitating condition where fibrosis develops in the fascia between the skin and tendons of the palm due to collagen accumulation, leading to permanently bent fingers and severely affecting the patient's quality of life. At present, no definitive cure exists for this condition.

*
Key Dupuytren's Disease Companies: Endo Pharmaceuticals/ Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others

*
Key Dupuytren's Disease Therapies: XIAFLEX (clostridium histolyticum), Anti-TNF drug adalimumab, VEN201, and others

*
The Dupuytren's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dupuytren's Disease pipeline products will significantly revolutionize the Dupuytren's Disease market dynamics.

*
A study conducted by Broekstra et al. (2022) identified 38,707 individuals with Dupuytren's disease in a population-based dynamic cohort, indicating a point prevalence of 0.67% in 2013. Of the affected individuals, 64.6% were male and 35.3% were female.

*
According to a study by Sasaki et al. (2021) conducted in Japan, Dupuytren's disease was identified in 44 individuals, reflecting an overall prevalence of 3.9%. Among men, the prevalence was 8.3%, while among women it was 1.3%. In participants over the age of 60, the prevalence increased to 7.7%-with 18.5% in men and 2.4% in women.

Dupuytren's Disease Overview

Dupuytren's Disease, also known as Dupuytren's Contracture, is a progressive hand condition where the connective tissue (fascia) under the skin of the palm thickens and tightens. Over time, this can cause one or more fingers-most commonly the ring and little fingers-to bend inward toward the palm, making it difficult to fully straighten them.

It typically develops slowly and is more common in older adults, particularly males of Northern European descent. While it is usually painless, it can impact hand function and quality of life in advanced cases. Treatment options range from non-surgical therapies like injections to surgical procedures to release the contracted tissue.

Get a Free sample for the Dupuytren's Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dupuytrens-disease-market [https://www.delveinsight.com/report-store/dupuytrens-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dupuytren's Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dupuytren's Disease Epidemiology Segmentation:

The Dupuytren's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Dupuytren's Disease

*
Prevalent Cases of Dupuytren's Disease by severity

*
Gender-specific Prevalence of Dupuytren's Disease

*
Diagnosed Cases of Episodic and Chronic Dupuytren's Disease

Download the report to understand which factors are driving Dupuytren's Disease epidemiology trends @ Dupuytren's Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dupuytren's Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dupuytren's Disease market or expected to get launched during the study period. The analysis covers Dupuytren's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dupuytren's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dupuytren's Disease Therapies and Key Companies

*
XIAFLEX (clostridium histolyticum): Endo Pharmaceuticals/ Asahi Kasei Pharma

*
Anti-TNF drug adalimumab: 180 Life Sciences

*
VEN201: Ventoux Biosciences

*
Adalimumab: 180 Life Sciences

Discover more about therapies set to grab major Dupuytren's Disease market share @ Dupuytren's Disease Treatment Landscape [https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dupuytren's Disease Market Drivers

*
Awareness of Dupuytren's Disease has improved over time, leading to earlier diagnosis and intervention.

*
There have been advancements in both surgical and non-surgical treatment options for Dupuytren's Disease, offering patients more choices for managing their condition.

Dupuytren's Disease Market Barriers

*
There is growing interest in minimally invasive treatment options for Dupuytren's Disease, which could offer reduced recovery times and improved patient outcomes.

*
Advancements in genetics and personalized medicine may lead to the development of tailored treatment approaches based on individual patient characteristics, potentially enhancing treatment efficacy

Scope of the Dupuytren's Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Dupuytren's Disease Companies: Endo Pharmaceuticals/ Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others

*
Key Dupuytren's Disease Therapies: XIAFLEX (clostridium histolyticum), Anti-TNF drug adalimumab, VEN201, and others

*
Dupuytren's Disease Therapeutic Assessment: Dupuytren's Disease current marketed and Dupuytren's Disease emerging therapies

*
Dupuytren's Disease Market Dynamics: Dupuytren's Disease market drivers and Dupuytren's Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Dupuytren's Disease Unmet Needs, KOL's views, Analyst's views, Dupuytren's Disease Market Access and Reimbursement

To know more about Dupuytren's Disease companies working in the treatment market, visit @ Dupuytren's Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Dupuytren's Disease Market Report Introduction

2. Executive Summary for Dupuytren's Disease

3. SWOT analysis of Dupuytren's Disease

4. Dupuytren's Disease Patient Share (%) Overview at a Glance

5. Dupuytren's Disease Market Overview at a Glance

6. Dupuytren's Disease Disease Background and Overview

7. Dupuytren's Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Dupuytren's Disease

9. Dupuytren's Disease Current Treatment and Medical Practices

10. Dupuytren's Disease Unmet Needs

11. Dupuytren's Disease Emerging Therapies

12. Dupuytren's Disease Market Outlook

13. Country-Wise Dupuytren's Disease Market Analysis (2020-2034)

14. Dupuytren's Disease Market Access and Reimbursement of Therapies

15. Dupuytren's Disease Market Drivers

16. Dupuytren's Disease Market Barriers

17. Dupuytren's Disease Appendix

18. Dupuytren's Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dupuytrens-disease-market-statistics-expected-to-experience-major-growth-by-2034-according-to-delveinsight-endo-pharma-asahi-kasei-pharma-180-life-sciences-ventoux-biosciences]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.